| |
* Trademark is the property of its owner.
|
|
 This novel study analyzed corneas from 48 patients undergoing penetrating keratoplasty. The controlled, randomized, open-label, multidose study compared the corneal penetration levels of VIGAMOX® solution (moxifloxacin, Alcon, Fort Worth, Texas) and ZYMAR* (gatifloxacin). Study eyes received two drops of either antibiotic five minutes apart, with the last dose at 0.25, 0.5, one, or two hours before corneal samples were assayed for moxifloxacin and gatifloxacin concentrations.
As the graph shows, the mean peak epithelial level of moxifloxacin was about sevenfold higher than gatifloxacin; the mean peak stromal level of moxifloxacin was about threefold higher than gatifloxacin mean peak stromal level; and the mean peak endothelial level of moxifloxacin was about tenfold higher than gatifloxacin. This indicates moxifloxacin provides enhanced penetration that should contribute to superior activity against common ocular pathogens associated with endophthalmitis and keratitis.
|
